SNT 2.94% 3.3¢ syntara limited

cash 2x market cap, page-19

  1. Neo
    2,195 Posts.
    ASX300 rebalancing should of already been done.

    If they can't resolve the "packing" issue with Aridol then it's another excuse to sell down. Also, I've considered the risk that Novaquest could cause a "black swan" event and decide they're not willing to front up with the additional 20 million, which is suppose to become available next year for another CF trial. 12 cents wouldn't be looking so cheap then.

    Buying at these levels does look attractive though, but buyer beware.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.